By abandoning oncology research, IGM reduced its year-over-year R&D expenses to $46.1 million from $54.8 million.
Anthony Duignan-Cabrera, Biz Journals
Mon, 11/11/2024 - 12:06pm
By abandoning oncology research, IGM reduced its year-over-year R&D expenses to $46.1 million from $54.8 million.